Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Christopher McGowan

Gastroenterology Cary, NC Medical Doctor

NPI 1720204241 CMS profile 1237738

2001 Weston Pkwy, Cary, NC 27513

Open in the dashboard

General payments

$222,598

211 records reported · program years 2019–2025

Research payments

$375

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$804,440 paid to institutions, not to them · program years 2023–2025

Through program year 2025, Christopher McGowan of Cary, NC is reported in the CMS Open Payments database as having received $222,598 across 211 general payments and $375 in research payments paid to them. Separately, studies naming them as principal investigator received $804,440 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $157,373 97
2024 General $17,469 9
2023 General $2,717 5
2022 General $15,879 16
2021 General $7,505 15
2021 Research $375 1
2020 General $11,223 20
2019 General $10,432 49

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christopher McGowan
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Christopher McGowan were reported at $157,373. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Christopher McGowan Gastroenterology median Middle half National median
2019 $10,432 $417 $126–$1,100 $163
2020 $11,223 $224 $74–$624 $114
2021 $7,505 $352 $106–$1,054 $132
2022 $15,879 $448 $129–$1,270 $149
2023 $2,717 $533 $150–$1,390 $160
2024 $17,469 $605 $160–$1,606 $164
2025 $157,373 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $97,035 74 payments
  2. Intuitive Surgical, Inc. $58,136 19 payments
  3. Apollo Endosurgery US Inc $44,094 59 payments
  4. Erbe Elektromedizin GmbH $12,897 6 payments
  5. Olympus Corporation of the Americas $9,798 13 payments
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $184 11 payments
  7. AbbVie, Inc. $176 12 payments
  8. Novo Nordisk Inc $76 4 payments
  9. Ferring Pharmaceuticals Inc. $64 4 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $45 4 payments
  11. Other $92 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $96,845 27 payments
  2. Consulting Fee $94,923 36 payments
  3. Travel and Lodging $18,942 42 payments
  4. Honoraria $8,325 3 payments
  5. Food and Beverage $3,563 103 payments
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System $58,136 19 payments
  2. OverStitch Endoscopic Suturing System OverStitch Endoscopic Suturing System 2-0 Polypropylene_ENDO $43,797 32 payments
  3. OverStitch NXT Endoscopic Suturing System $22,281 10 payments
  4. OverStitch Endoscopic Suturing System Endoscopic Tissue Approximation Device $19,609 26 payments
  5. Overstitch $17,084 26 payments
  6. OverStitch Endoscopic Suturing System Sx $15,325 10 payments
  7. ORBERA Intragastric Balloon System $13,934 5 payments
  8. General - Therapies $10,928 8 payments
  9. X-Tack Endoscopic HeliX Tacking System Endoscopic Tissue Approximation Device $7,006 9 payments
  10. X-Tack Endoscopic HeliX Tacking System Endoscopic Tissue Approximation Device $7,006 9 payments
  11. Other $15,858 76 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Erbe Elektromedizin GmbH $375 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

13

Median for Internal Medicine: 777

Drug cost

$216

Median for Internal Medicine: $73,373

Branded share of claims

0%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Omeprazole Generic 13 $216

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Records

212 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record